People taking semaglutide for type 2 diabetes were no more likely to develop pancreatic cancer than people using other diabetes drugs, according to a large Nordic registry study presented this week at the annual meeting of the European Association for the Study of Diabetes in Milan. The findings address one of the most persistent fears among Ozempic users. The reassurance comes with a clear limit, however: average follow-up lasted less than two years after a one-year waiting period.
That timeline matters because pancreatic cancer can take years to develop. The study was also funded by Novo Nordisk, the company that makes Ozempic and Wegovy, and it has not yet been submitted to a medical journal. For U.S. patients, the result is encouraging news, not a final answer.
